GSK3B
Glycogen synthase kinase 3β (GSK3β) is a serine/threonine protein kinase with broad roles in cell signaling, metabolism, and stress-response pathways.
Glycogen synthase kinase 3β (GSK3β) is a serine/threonine protein kinase with broad roles in cell signaling, metabolism, and stress-response pathways. It is one of two closely related GSK3 isoforms and is widely studied because of its involvement in phosphorylation-dependent regulation of proteins that influence neuronal function, inflammatory signaling, and metabolic homeostasis. In biomedical research, GSK3β is often discussed as a signaling hub rather than a single-pathway enzyme, since its activity can intersect with pathways such as AMPK/mTOR, β-catenin-related signaling, and kinase networks involving Protein Kinase C Alpha (PKCα).
Because of this central position, GSK3β has attracted attention as a therapeutic target in neurodegenerative disease, cancer-related signaling, and metabolic disorders. In the recent studies summarized here, it was investigated in contexts ranging from Alzheimer’s disease-related pathology, including tau and Amyloid beta (Aβ)-associated mechanisms, to endothelial dysfunction in Metabolic dysfunction associated steatohepatitis (MASH). These studies reinforce the view that GSK3β can influence both neuronal and vascular disease processes through phosphorylation-dependent control of downstream targets.
Where the papers sit
17 papers from the last 6 months study GSK3B directly · updated from PubMed 9 Nov 2026
Study type 0 clinical trials · 3 human data · 14 preclinical
Themes 3 themes · 1 new direction
-
GSK3B Drug Discovery
GSK3B drug discovery is spanning pulmonary fibrosis, solid tumors, prion synaptotoxicity, and Rett syndrome. Network pharmacology, docking, molecular dynamics, ADMET, and machine learning are used to connect compounds with polypharmacologic targets. Antiproliferative hybrids, Schisandrin A, SB216763, trofinetide, and XIAP–PKC pathway inhibition provide distinct candidate routes, including PD-1 resensitization. The shared direction is target and mechanism prioritization rather than a single disease program, so therapeutic validation remains preliminary.
7 papers · 41.2%
-
GSK3B in Cognitive Dysfunction
GSK3B modulation is being pursued to protect cognition and neurons from tau pathology, oxidative stress, and apoptosis. Cistanoside A targets tau hyperphosphorylation through AKT/GSK3β, while quercetin engages microglial polarization and miR-379-5p in postoperative cognitive dysfunction. Isoorientin and GSK3β inhibition connect Nrf2 activation or restored synaptic and mitochondrial function to better cognitive outcomes. PI3K/Akt signaling also appears in diabetic nephropathy, but whether these preclinical benefits translate to durable human cognitive improvement remains unresolved.
6 papers · 35.3%
-
GSK3B in Tissue Injury
PI3K/AKT–GSK3β signaling is being targeted to limit inflammatory and ischemic tissue injury. Cottonseed oil and nuciferine link pathway modulation to reduced neuroinflammation, oxidative stress, and mPTP opening after brain injury. SIRT3-mediated GSK3β deacetylation extends the mechanism to diabetic myocardial fibrosis. Computational pharmacophore, docking, ADME, and dynamics studies are shifting the field toward candidate GSK3β inhibitors for Alzheimer disease, but clinical relevance remains open.
4 papers · 23.5%
GSK3β activation, rather than inhibition, can restore immune-checkpoint sensitivity
Anti-PD-1-refractory tumors were found to respond to pan-PKC inhibition through GSK3β activation, which promoted tumor-intrinsic PD-L1 degradation and enhanced CD8+ T-cell recruitment and function, instead of treating GSK3β inhibition as the therapeutic endpoint. This assigns GSK3β a new role as an effector of immunogenic tumor resensitization in checkpoint-refractory cancer, with the therapeutic implication that activating—not suppressing—GSK3β may help overcome resistance to immunotherapy 42234523Jun.
Papers
The 17 papers from the last 6 months that study GSK3B directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
GSK3B Drug Discovery (7)
- Exploring the Molecular Mechanisms of SB216763 in the Therapeutic Intervention of Pulmonary Fibrosis Based on Macrophage Functional Plasticity. Fundamental & clinical pharmacology · 18 Aug 2026 PMID 42613038
- Mapping Trofinetide Polypharmacology in Rett Syndrome: A Multi-Stage Computational Analysis. Journal of computational chemistry · 30 Jul 2026 PMID 42530159
- Fluorinated isoindolinone-amino acid hybrids possessing antiproliferative and antitumor activity in vitro and in vivo. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 21 Jul 2026 PMID 42480152
- Chemo-omic pipeline enables discovery of prion synaptotoxic pathways and inhibitory drugs. PLoS pathogens · 18 Jun 2026 PMID 42313800
- Targeting XIAP-coordinated PKC signaling resensitizes PD-1-refractory tumors for rechallenge. Proceedings of the National Academy of Sciences of the United States of America · 3 Jun 2026 PMID 42234523
- Integrated Network Pharmacology and Machine Learning to Reveal the Mechanisms of Schisandrin A Against Triple-Negative Breast Cancer. Journal of cellular and molecular medicine · 1 Jun 2026 PMID 42220063
- Studies of design, synthesis and biological properties, ADMET profiling, molecular docking, network pharmacology and molecular dynamics simulation of novel chalcone derivatives containing benzoyl-piperazin. Bioorganic chemistry · 21 May 2026 PMID 42166963
GSK3B in Cognitive Dysfunction (6)
- Isoorientin inhibits oxidative stress to ameliorate cognitive dysfunction in type 2 diabetes mice via GSK3β/Nrf2 axis. Metabolic brain disease · 17 Jul 2026 PMID 42467274
- Cistanoside A decreases Tau hyperphosphorylation and neuronal apoptosis through the AKT/GSK3β pathway in okadaic acid-induced in vivo and in vitro models of Alzheimer's disease. Molecular biology reports · 9 Jul 2026 PMID 42423799
- Inotodiol ameliorates oxidative stress and apoptosis by regulating PI3K/Akt/GSK-3β signaling pathways in diabetic nephropathy. Renal failure · 29 Jun 2026 PMID 42367005
- Glycogen Synthase Kinase-3β Inhibition Ameliorates Synaptic and Mitochondrial Dysfunction in a Sporadic Alzheimer's Disease-Like Model. Molecular neurobiology · 17 Jun 2026 PMID 42307791
- Quercetin Alleviates Postoperative Cognitive Dysfunction of Aged Mice by Regulating Microglial Polarization through Inducing miR-379-5p RNA Modification. Molecular neurobiology · 28 May 2026 PMID 42209865
- Mild Cognitive Impairment Associated with Obstructive Sleep Apnoea: A Pilot Study on Oxygen-Related Plasma Biomarkers and Network Analysis. Molecular neurobiology · 21 May 2026 PMID 42168722
GSK3B in Tissue Injury (4)
- Cottonseed Oil Attenuates Traumatic Brain Injury by Inhibiting AKT/GSK-3β-mediated Neuroinflammatory Responses. Molecular neurobiology · 29 Aug 2026 PMID 42668334
- Nicotinamide Mononucleotide Ameliorates Myocardial Fibrosis in Diabetic Mice Possibly by Modulating SIRT3 to Deacetylate GSK3β and Thereby Reducing the Phosphorylation of Smad3. Journal of cardiovascular translational research · 10 Aug 2026 PMID 42573891
- In silico pipeline for GSK 3β inhibitor discovery in Alzheimer's disease using pharmacophore screening, docking, ADME filtering, and MD validation. Scientific reports · 23 Jul 2026 PMID 42493523
- Nuciferine alleviates cerebral ischemia-reperfusion injury by inhibiting mPTP opening via activating the phosphatidylinositol 3-kinase/protein kinase B/glycogen synthase kinase 3 beta pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology · 22 May 2026 PMID 42172986
By study type
Human data, design not indexed (3)
- Mapping Trofinetide Polypharmacology in Rett Syndrome: A Multi-Stage Computational Analysis. Journal of computational chemistry · 30 Jul 2026 PMID 42530159
- In silico pipeline for GSK 3β inhibitor discovery in Alzheimer's disease using pharmacophore screening, docking, ADME filtering, and MD validation. Scientific reports · 23 Jul 2026 PMID 42493523
- Mild Cognitive Impairment Associated with Obstructive Sleep Apnoea: A Pilot Study on Oxygen-Related Plasma Biomarkers and Network Analysis. Molecular neurobiology · 21 May 2026 PMID 42168722
Preclinical: animal, cell and lab studies (14)
- Cottonseed Oil Attenuates Traumatic Brain Injury by Inhibiting AKT/GSK-3β-mediated Neuroinflammatory Responses. Molecular neurobiology · 29 Aug 2026 PMID 42668334
- Exploring the Molecular Mechanisms of SB216763 in the Therapeutic Intervention of Pulmonary Fibrosis Based on Macrophage Functional Plasticity. Fundamental & clinical pharmacology · 18 Aug 2026 PMID 42613038
- Nicotinamide Mononucleotide Ameliorates Myocardial Fibrosis in Diabetic Mice Possibly by Modulating SIRT3 to Deacetylate GSK3β and Thereby Reducing the Phosphorylation of Smad3. Journal of cardiovascular translational research · 10 Aug 2026 PMID 42573891
- Fluorinated isoindolinone-amino acid hybrids possessing antiproliferative and antitumor activity in vitro and in vivo. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 21 Jul 2026 PMID 42480152
- Isoorientin inhibits oxidative stress to ameliorate cognitive dysfunction in type 2 diabetes mice via GSK3β/Nrf2 axis. Metabolic brain disease · 17 Jul 2026 PMID 42467274
- Cistanoside A decreases Tau hyperphosphorylation and neuronal apoptosis through the AKT/GSK3β pathway in okadaic acid-induced in vivo and in vitro models of Alzheimer's disease. Molecular biology reports · 9 Jul 2026 PMID 42423799
- Inotodiol ameliorates oxidative stress and apoptosis by regulating PI3K/Akt/GSK-3β signaling pathways in diabetic nephropathy. Renal failure · 29 Jun 2026 PMID 42367005
- Chemo-omic pipeline enables discovery of prion synaptotoxic pathways and inhibitory drugs. PLoS pathogens · 18 Jun 2026 PMID 42313800
- Glycogen Synthase Kinase-3β Inhibition Ameliorates Synaptic and Mitochondrial Dysfunction in a Sporadic Alzheimer's Disease-Like Model. Molecular neurobiology · 17 Jun 2026 PMID 42307791
- Targeting XIAP-coordinated PKC signaling resensitizes PD-1-refractory tumors for rechallenge. Proceedings of the National Academy of Sciences of the United States of America · 3 Jun 2026 PMID 42234523
- Integrated Network Pharmacology and Machine Learning to Reveal the Mechanisms of Schisandrin A Against Triple-Negative Breast Cancer. Journal of cellular and molecular medicine · 1 Jun 2026 PMID 42220063
- Quercetin Alleviates Postoperative Cognitive Dysfunction of Aged Mice by Regulating Microglial Polarization through Inducing miR-379-5p RNA Modification. Molecular neurobiology · 28 May 2026 PMID 42209865
- Nuciferine alleviates cerebral ischemia-reperfusion injury by inhibiting mPTP opening via activating the phosphatidylinositol 3-kinase/protein kinase B/glycogen synthase kinase 3 beta pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology · 22 May 2026 PMID 42172986
- Studies of design, synthesis and biological properties, ADMET profiling, molecular docking, network pharmacology and molecular dynamics simulation of novel chalcone derivatives containing benzoyl-piperazin. Bioorganic chemistry · 21 May 2026 PMID 42166963
Written from 17 PubMed abstracts, each one listed by PMID above. Published: 2026-06-24. Last written: 2026-08-31 by GPT. Drafted by language models from published abstracts; not medical advice.